ClinicalTrials.gg
Active, not recruitingNCT05521438Updated Mar 16, 2026

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

A Phase 2/3 interventional study of QRX003-2% Lotion and QRX003-4% Lotion QAM in Netherton Syndrome, sponsored by Quoin Pharmaceuticals. Active, not recruiting at 5 sites in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Quoin Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Netherton Syndrome with a site in United States — 4 open to participants now, 6 under way, 4 of them phase 3. Netherton Syndrome · United States.

Planned enrollment
4th of 12
30 · median 20
Started
2022
with 2 others
Phase 2/3
5 of 14
3 open now
Registered
6th of 14
by date
Lead sponsor
4 of 14
Quoin Pharmaceuticals

Among the 14 studies in Netherton Syndrome with a site in United States, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 5 in phase 2/3, and was the 6th registered.

Netherton Syndrome

22 studies on the registry are indexed under Netherton Syndrome; 5 are open to participants now.

Browse Netherton Syndrome studies →

Open to participants now

4 of the 14 studies in Netherton Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Netherton Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Netherton Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

03

Conditions studied

  • Netherton Syndrome

Browse trials for

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a male or non-pregnant female at least 14 years of age.
  • Females must be , surgically sterile , or use an effective method of , for the duration of the study and for 3 months following completion of treatment. Women of (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline.
  • Subject has a clinical diagnosis of NS and agrees to genetic testing at Visit 1/Screening for confirmation of NS diagnosis if the subject does not have test results confirming a SPINK5 mutation.
  • Subject has NS lesions in the Treatment Area (i.e., arms or lower legs).
  • Subject is in good general health and free of any disease state or physical condition that might impair evaluation of NS or exposes the subject to an unacceptable risk by study participation.

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant, lactating, or is planning to become pregnant during the study.
  • Subject has any skin pathology in the Treatment Area or condition that, could interfere with the evaluation of the test article or requires use of interfering topical, systemic, or surgical therapy.
  • Subject has Fridericia- ≥ 450 ms for males or ≥ 470 ms for females
  • Subject has active cancer of any type excluding non-melanoma skin cancer outside of the Treatment Area.
  • Subject has diabetes of any type, except non-insulin dependent diabetes mellitus that is reasonably controlled.
  • Subject has evidence of active infection during screening, or serious infection within 30 days prior to Visit 2/Baseline.
  • Subject has known , or C virus, or active or latent tuberculosis.
  • Subject has used ultraviolet phototherapy within the Treatment Area within 4 weeks prior to Visit 2/Baseline.
  • Subject has used systemic prescription treatment for NS within 4 weeks prior to Visit 2/Baseline.
  • Subject has used systemic biologic therapy for NS.
  • Subject has used topical prescription treatment in the Treatment Area within 2 weeks prior to Visit 2/Baseline.
  • Subject has used any topical bland moisturizers/emollients in the Treatment Area within 24 hours prior to Visit 2/Baseline.
  • Subject is currently enrolled in an drug, biologic, or device study.
  • Subject has used an investigational drug, biologic, or device treatment within 30 days prior to Visit 2/Baseline.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    QRX003-2% QAM

    Subjects will apply test article once daily in the morning (QAM) for 12 weeks

    Drug: QRX003-2% Lotion

  • Experimental
    QRX003-4% QAM

    Subjects will apply test article once daily in the morning (QAM) for 12 weeks

    Drug: QRX003-4% Lotion QAM

  • Experimental
    Vehicle Lotion

    Subjects will apply test article once daily in the morning (QAM) for 12 weeks

    Drug: Vehicle

  • Experimental
    QRX003-4% BID

    Subjects will apply test article twice daily BID for 12 weeks

    Drug: QRX003-4% Lotion BID

Interventions

  • QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)

  • QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

  • DrugVehicle

    Vehicle Lotion

  • QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

06

What researchers measure

Primary outcomes

  1. Efficacy Endpoints-1-point IGA

    Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline. The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

    Time frame: Up to week 16

  2. Efficacy Endpoints-2-point IGA

    Proportion of subjects with 2-point reduction in IGA from Baseline.

    Time frame: Up to week 16

  3. Efficacy Endpoints-NS Sign

    Change from Baseline in each individual NS Sign (erythema and scaling). Severity of each NS sign is graded on a 5-point scale.

    Time frame: Up to week 16

  4. Efficacy Endpoints-BSA

    Change from Baseline in total Body Surface Area (BSA) affected by NS in the Treatment Area

    Time frame: Up to week 16

  5. Efficacy Endpoints-WI-NRS score

    Change from Baseline in the Worst Itch-Numeric Rating Scale (WI-NRS) score. Itch severity is graded on an 11-point scale where 0 represents "no itch" and 10 represents "worst itch imaginable".

    Time frame: Up to week 16

  6. Efficacy Endpoints-TSQM

    Assessment of subject satisfaction with treatment based on the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM measures a subject's level of satisfaction or dissatisfaction with the treatment. Composite scores can range from 0 to 100; higher scores indicate better satisfaction.

    Time frame: Up to week 16

  7. Efficacy Endpoints-Rescue Therapy

    Proportion of subjects requiring rescue therapy

    Time frame: Up to week 16

  8. Safety Endpoints-AEs

    Any local and systemic AEs (Adverse Events)/serious AEs

    Time frame: Up to week 16

  9. Safety Endpoints-LSR

    Number of subjects with presence of the following LSRs (Local Skin Reactions): edema, excoriations, oozing/vesiculation/crusting, and erosions at any study visit.

    Time frame: Up to week 16

07

Study locations

5 sites
  • Site #1
    San Diego, California 92123, United States
  • Site #4
    Indianapolis, Indiana 46250, United States
  • Site #5
    Quincy, Massachusetts 02169, United States
  • Site #3
    Charleston, South Carolina 29425, United States
  • Site #2
    San Antonio, Texas 72218, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Dec 2025, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2022
First posted
Aug 30, 2022
StartActual
Jun 23, 2022
Primary completionActual
Dec 30, 2025
CompletionEst.
Dec 31, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05521438
Lead sponsor
Quoin Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 30, 2022
Start date
Jun 23, 2022
Primary completion
Dec 30, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Tony Andrasfay
study director · Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QRX003

Start the discussion